Plasminogen Activator Acrosine Substrate

<strong>Plasminogen Activator Acrosine Substrate</strong>_x000D_ <strong>Catalog number:</strong> B2011348_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 633.6 g/mol_x000D_ <strong>Supplied as:</strong> Lyophilized_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> AFC_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Daehn IS, Duffield JS. The glomerular filtration barrier: a structural target for novel kidney therapies Nat Rev Drug Discov. 2021 Oct;20(10):770-788._x000D_ 2: Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells J Biol Chem. 1998 Jul 17;273(29):18268-72._x000D_ 3: Skogseth H, Larsson E, Halgunset J. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells APMIS. 2005 May;113(5):332-9._x000D_ 4: Shi Z, Liu Y, Johnson JJ, Stack MS. Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas Mol Cell Biochem. 2011 Nov;357(1-2):151-61._x000D_ 5: Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, Milev P, Bugge TH, Degen JL, Levine JM, Margolis RU, Tsirka SE. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate J Cell Biol. 2000 Mar 20;148(6):1295-304._x000D_ 6: Castorina A, D'Amico AG, Scuderi S, Leggio GM, Drago F, D'Agata V. Dopamine D3 receptor deletion increases tissue plasminogen activator (tPA) activity in prefrontal cortex and hippocampus Neuroscience. 2013 Oct 10;250:546-56._x000D_ 7: Andersen LM, Wind T, Hansen HD, Andreasen PA. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue Biochem J. 2008 Jun 15;412(3):447-57._x000D_ 8: Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease Clin Biochem. 2009 Sep;42(13-14):1331-46._x000D_ 9: Yebra M, Goretzki L, Pfeifer M, Mueller BM. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction Exp Cell Res. 1999 Jul 10;250(1):231-40._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/1315765">10: Bassel-Duby R, Jiang NY, Bittick T, Madison E, McGookey D, Orth K, Shohet R, Sambrook J, Gething MJ. Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor J Biol Chem. 1992 May 15;267(14):9668-77.</a>_x000D_ _x000D_ <strong>Products Related to Plasminogen Activator Acrosine Substrate can be found at</strong> <a href="https://moleculardepot.com/product-category/Substrates/"> Substrates</a>